#Bdx

BD Announces Record Date for the Spin-Off of its Biosciences & Diagnostic Solutions Business BD (NYSE: BDX) set Feb 5, 2026 as the record date for the spin-off of its Biosciences & Diagnostic Solutions business and expects to combine the spun-off unit with Waters (NYSE: WAT) via a Reverse Morris Trust on Feb 9, 2026, subject to customary closing conditions.Under the terms, BD will receive $4 billion cash, and BD shareholders will receive Waters common stock representing 39.2% of the combined company on a fully diluted basis; Waters shareholders will own 60.8%.Shares will trade with due bills starting Feb 5 and trade ex-distribution after closing; BD received a favorable IRS private letter ruling.

1 month ago

#BDX #WAT BD Announces Record Date for the Spin-Off of its Biosciences & Diagnostic Solutions Business

www.stocktitan.net/news/BDX/bd-announces-re...

0 0 0 0

Waters Shareholders Approve Combination with BD's Biosciences & Diagnostic Solutions Business Waters (NYSE: WAT) shareholders approved issuing Waters common stock to shareholders of Becton, Dickinson and Company (NYSE: BDX) for the proposed combination of BD's Biosciences & Diagnostic Solutions business with Waters, with preliminary voting showing ~99% support.Waters and BD received all required regulatory approvals and BD obtained a favorable IRS Private Letter Ruling on U.S. federal tax matters. The transaction is expected to close on February 9, 2026, subject to customary closing conditions. Waters will release Q4 2025 results and hold a conference call and webcast on February 9, 2026 at 8:30 a.m. ET; a replay will be available through at least March 9, 2026.

1 month ago

#BDX #WAT Waters Shareholders Approve Combination with BD's Biosciences & Diagnostic Solutions Business

www.stocktitan.net/news/BDX/waters-sharehol...

0 0 0 0

BD Helps Scientists Advance Immunology and Cancer Research with AI-Powered Insights and Automation BD (NYSE: BDX) announced the global commercial release of BD Research Cloud 7.0 on January 23, 2026, introducing BD Horizon Panel Maker, an AI-powered tool for automated panel design to support immunology and cancer research.The cloud-based platform supports collaboration, workflow streamlining and lab operations management, and the new AI tool generates optimized panel recommendations within seconds from custom inputs or curated validated databases. The release highlights integrated visualization features (comparison tables and complexity scores) and explicit support for imaging and spectral panel design with BD FACSDiscover instruments. BD Research Cloud 7.0 is commercially available at bdresearchcloud.com.

1 month ago

#BDX BD Helps Scientists Advance Immunology and Cancer Research with AI-Powered Insights and Automation

www.stocktitan.net/news/BDX/bd-helps-scient...

0 0 0 0

BD and Ypsomed Expand Partnership to Address Rapidly Growing Biologics Market The enhanced collaboration and innovation will improve options for pharmaceutical companies and patients requiring large-volume self-injection systems. LE PONT-DE-CLAIX, France and BURGDORF, Switzerland, Jan. 21, 2026/ PRNewswire/-- BD, a leading global medical technology company, and Ypsomed, a leading developer of injection systems, are strengthening...

1 month ago

#BDX BD and Ypsomed Expand Partnership to Address Rapidly Growing Biologics Market

www.stocktitan.net/news/BDX/bd-and-ypsomed-...

0 0 0 0

BD Receives FDA 510(k) Clearance for EnCor EnCompass™ Breast Biopsy and Tissue Removal System BD (NYSE: BDX) received FDA 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal System on January 15, 2026. The multi-modality biopsy system is designed to work across breast imaging platforms, offering adjustable vacuum strengths, a variable sample notch, 360° sampling, echogenic cutting cannula, illuminated sample container, and probe choices of 12G, 10G, and 7G. The system is expected to enter the market in early 2026, expanding BD's breast health portfolio to support earlier detection and diagnosis.

2 months ago

#BDX BD Receives FDA 510(k) Clearance for EnCor EnCompass™ Breast Biopsy and Tissue Removal System

www.stocktitan.net/news/BDX/bd-receives-fda...

0 0 0 0

BD Announces $110 Million to Support U.S. Pharmaceutical Supply Chain for Biologic Drugs BD (NYSE: BDX) announced a $110 million investment to expand production of BD Neopak™ Glass Prefillable Syringes in Columbus, Nebraska, creating about 120 jobs and strengthening U.S. pharmaceutical supply chains.The plan allocates $100 million for Neopak syringe production with supply expected in mid-2026 and $10 million to enhance cannula manufacturing; it follows a prior >$35 million Columbus expansion and sits within a broader pledge to invest $2.5 billion in U.S. manufacturing over five years.

2 months ago

#BDX BD Announces $110 Million to Support U.S. Pharmaceutical Supply Chain for Biologic Drugs

www.stocktitan.net/news/BDX/bd-announces-11...

0 0 0 0

BD Marks Milestone with First Phasix™ Hernia Prevention Case in Greece and Over 85% Enrollment in U.S. PREVENT Trial BD (NYSE: BDX) announced the first prophylactic use of Phasix™ Mesh in Greece following its expanded CE-marked prophylactic indication in Europe, with the procedure performed at George Papanikolaou General Hospital in Thessaloniki.The company reported the multicenter randomized PREVENT trial is >85% enrolled and is projected to complete enrollment in 2026, with results intended to support a U.S. PMA submission for incisional hernia prevention. Phasix launched three new sizes in 2025 and is registered in the U.K. Phasix is not indicated for hernia prevention in the United States.

2 months ago

#BDX BD Marks Milestone with First Phasix™ Hernia Prevention Case in Greece and Over 85% Enrollment in U.S. PREVENT Trial

www.stocktitan.net/news/BDX/bd-marks-milest...

0 0 0 0

BD and Penn Institute for Immunology and Immune Health Collaborate to Advance Immunotherapy through Flow Cytometry BD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000- Person Immune Profiling Study. FRANKLIN LAKES, N.J., Dec. 18, 2025/ PRNewswire/-- BD, a leading global medical technology company, today announced a strategic collaboration with the Institute for Immunology...

2 months ago

#BDX BD and Penn Institute for Immunology and Immune Health Collaborate to Advance Immunotherapy through Flow Cytometry

www.stocktitan.net/news/BDX/bd-and-penn-ins...

0 0 0 0

BD and ChemoGLO™ Collaborate to Expand Hazardous Drug Contamination Testing for Health Care Facilities and Laboratories BD (NYSE: BDX) and ChemoGLO announced a strategic collaboration to expand hazardous drug contamination testing for health care facilities and laboratories.The partnership pairs the BD HD Check System — providing qualitative, point-of-care results in 10 minutes — with ChemoGLO's LC-MS/MS quantitative analysis, which delivers an expanded hazardous‑drug panel report within 3–5 days after sample receipt. The workflow uses BD HD Check collection kits for safe shipping to ChemoGLO for follow-up testing.The combined approach aims to help facilities quickly identify contamination and gain deeper quantitative insights to better protect health care workers. BD and ChemoGLO will be at the ASHP Midyear Clinical Meeting in Las Vegas, Dec 6–10, 2025 (BD Booth 1017; ChemoGLO Booth 1873).

3 months ago

#BDX BD and ChemoGLO™ Collaborate to Expand Hazardous Drug Contamination Testing for Health Care Facilities and Laboratories

www.stocktitan.net/news/BDX/bd-and-chemo-gl...

0 0 0 0

3 months ago

Beldex Bridge

Seamless Asset Transfers Powered by Beldex BSC Bridge
Seamlessly move #BDX across chains with the Beldex Binance Smart Chain Bridge! 🌉 1:1 pegged BDX ensures secure swaps, unlocking faster transactions & #DeFi access while keeping decentralization intact. 🔗 bridge.beldex.io
#BSC #Crosschain #Beldex

0 0 1 0

BD Onclarity™ HPV Assay for BD COR™ and BD Viper™ LT Systems Receive WHO Prequalification BD (NYSE: BDX) announced that the CE-marked BD Onclarity HPV Assay for the BD COR and BD Viper LT systems received WHO prequalification on November 17, 2025, enabling wider use in low- and middle-income countries.The assay detects 14 high-risk HPV types with extended genotyping (six individual types plus three genotype groups), supports self-collection including at-home where CE is recognized, and targets improved risk stratification and follow-up. The BD COR offers ~1,650-test capacity and up to 1,000 results in 24 hours; BD Viper LT provides compact, decentralized molecular testing.

3 months ago

#BDX BD Onclarity™ HPV Assay for BD COR™ and BD Viper™ LT Systems Receive WHO Prequalification

www.stocktitan.net/news/BDX/bd-onclarity-tm...

0 0 0 0

Duncan Regional Hospital Becomes First in U.S. to Implement BD Alaris™ EMR Infusion Interoperability with MEDITECH BD (NYSE: BDX) announced on November 13, 2025 that Duncan Regional Hospital is the first U.S. hospital to go live with BD Alaris™ EMR Infusion Interoperability integrated with MEDITECH. The integration enables bi-directional communication between MEDITECH and Alaris infusion pumps, allowing clinicians to scan to verify patients, medications and pumps; send infusion orders from MEDITECH to pumps; and receive infusion status back into the EHR.The rollout expands BD's market-leading interoperability—now live at more than 960 U.S. sites—to all three leading U.S. EHRs, and BD reports a pace of about 12 new site activations per month.

4 months ago

#BDX Duncan Regional Hospital Becomes First in U.S. to Implement BD Alaris™ EMR Infusion Interoperability with MEDITECH

www.stocktitan.net/news/BDX/duncan-regional...

0 0 0 0

BD Expands PureWick™ Portfolio with First-of-its-Kind Portable Solution to Confidently Manage Urinary Incontinence On the Go BD (NYSE: BDX) on Nov 12, 2025 introduced the PureWick™ Portable Collection System, a battery-powered, non-invasive urine management device designed for wheelchair users and mobile use.Key facts: the device offers up to 8 hours battery life, is mountable or carriable, compatible with PureWick™ male and female external catheters, and is sold via PureWickAtHome.com and phone ordering. The PureWick portfolio has sold > 55 million external catheters and is used in > 4,500 hospitals and rehab facilities in the U.S.; a survey of 150 users/caregivers found > 90% would recommend the PureWick urine collection system. BD positions the portable unit to improve mobility, discretion, and skin protection for people managing urinary incontinence.

4 months ago

#BDX BD Expands PureWick™ Portfolio with First-of-its-Kind Portable Solution to Confidently Manage Urinary Incontinence On the Go

www.stocktitan.net/news/BDX/bd-expands-pure...

0 0 0 0

4 months ago

BDX in Action: Unlocking Crypto Market Opportunities
🚀 #BDX in Action: Experience the power of real-world #crypto utility! From confidential transactions to #cross-chainswaps, BDX is unlocking new market opportunities and redefining how value moves in #Web3.
💥 #Beldex #CryptoInnovation

0 0 0 0

BD Achieves Milestone in AGILITY Study of Revello™ Vascular Covered Stent for Treatment of Peripheral Artery Disease BD (NYSE: BDX) announced on November 4, 2025 that the AGILITY IDE study has achieved full enrollment of the common and external iliac artery cohort (n=118) for the Revello™ Vascular Covered Stent in peripheral artery disease (PAD).The multi-center, prospective AGILITY study (NCT06111469) is enrolling at up to 45 sites across the United States, Europe, Australia and New Zealand and includes a second cohort for superficial femoral and proximal popliteal arteries (n=223) with enrollment ongoing. The milestone was announced during a late-breaking presentation at VIVA 2025 by Dr. Sean Lyden.

4 months ago

#BDX BD Achieves Milestone in AGILITY Study of Revello™ Vascular Covered Stent for Treatment of Peripheral Artery Disease

www.stocktitan.net/news/BDX/bd-achieves-mil...

0 0 0 0

4 months ago

1 0 1 0

BD Receives FDA 510(k) Clearance and CE-IVDR Certification for High-Throughput Enteric Bacterial Panels on BD COR™ System FRANKLIN LAKES, N.J., Nov. 3, 2025/ PRNewswire/-- BD a leading global medical technology company, today announced it has received U.S. Food and Drug Administration 510 clearance and Conformité Européenne marking in the European Union for its Enteric Bacterial Panel* and Enteric Bacterial Panel plus* for the BD COR™ System. By leveraging advanced Polymerase Chain...

4 months ago

#BDX BD Receives FDA 510(k) Clearance and CE-IVDR Certification for High-Throughput Enteric Bacterial Panels on BD COR™ System

www.stocktitan.net/news/BDX/bd-receives-fda...

0 0 0 0

4 months ago

#BDX masternode owners earn ~8.55 $BDX daily or 3,124 $BDX yearly per node. 🎯 It’s not just #passiveincome — it’s a commitment to powering #privacy, decentralization, and the future of confidential #blockchain networks. 🚀 #BDXRewards

1 0 0 0

E2S Conseil & Formation

@e2s-scop.bsky.social

4 months ago

Le Forum mondial de l’ESS Bordeaux GSEF 2025 c'est parti !

Notre agence y participe pour rencontrer, échanger et s’inspirer des initiatives qui font bouger l’économie sociale et solidaire à l’échelle mondiale 🌍

#GSEF2025 #BordeauxGSEF2025 #ESS #Bordeaux #BDX #GSEF

1 0 0 0

4 months ago

Manage BDX Seamlessly: Swap, Host & Buy BNS Domains
🚀 Manage your $BDX like never before!
The Beldex Electron Wallet now lets you swap crypto, host masternodes, and buy BNS domains — all in one place.
Your confidential Web3 journey just got smoother. 🌐✨
#Beldex #CryptoWallet #BDX

0 0 0 0

BD Simplifies At-Home HPV Testing to Broaden Access to Cervical Cancer Screening Outside United States FRANKLIN LAKES, N.J., Oct. 22, 2025/ PRNewswire/-- BD, a leading global medical technology company, today announced a new self-collection solution for HPV testing in markets outside the United States. This new innovation simplifies at-home sample collection for patients and further automates lab processing using high-tech robotics with the BD COR™ System.

4 months ago

#BDX BD Simplifies At-Home HPV Testing to Broaden Access to Cervical Cancer Screening Outside United States

www.stocktitan.net/news/BDX/bd-simplifies-a...

0 0 0 0

ASX Market Sensitive Announcements

@asxmktsensitive.bsky.social

4 months ago

BCAL Diagnostics share price BCAL Diagnostics (ASX:BDX) is an asset listed on the ASX, and part of the Health Care sector. Grafa’s asset page shows BCAL Diagnostics’s share price, chart, tr

BCAL Diagnostics ( #BDX ) has released " BCAL Establishes $10 million Convertible Note Facility " on Mon 20 Oct at 08:28 AEST #Australia #media #Strategy #live #ASX

0 0 0 0

BD Reaches Major Milestone for Rotarex™ Catheter System with First Patient Enrolled in XTRACT™ Registry to Advance Real-World Evidence in Peripheral Artery Disease FRANKLIN LAKES, N.J., Oct. 9, 2025/ PRNewswire/-- BD, a leading global medical technology company, today announced the enrollment of the first patient in the XTRACT™ Registry, a prospective, multi-center, single-arm, post-market registry study designed to evaluate the real-world performance of the Rotarex™ Catheter System in the treatment of patients with...

5 months ago

#BDX BD Reaches Major Milestone for Rotarex™ Catheter System with First Patient Enrolled in XTRACT™ Registry to Advance Real-World Evidence in Peripheral Artery Disease

www.stocktitan.net/news/BDX/bd-reaches-majo...

0 0 0 0

ASX Market Sensitive Announcements

@asxmktsensitive.bsky.social

5 months ago

BCAL Diagnostics share price BCAL Diagnostics (ASX:BDX) is an asset listed on the ASX, and part of the Health Care sector. Grafa’s asset page shows BCAL Diagnostics’s share price, chart, tr

BCAL Diagnostics ( #BDX ) has released " BCAL and ClearNote Partner on Early Cancer Detection Tests " on Thu 18 Sep at 10:00 AEST #ArtificialIntelligence #UnitedStates #Australia #media #live

2 0 0 0

BD Reports Third Quarter Fiscal 2025 Financial Results BD (NYSE:BDX) reported strong Q3 fiscal 2025 results with revenue reaching $5.5 billion, up 10.4% as reported and 3.0% organic. The company delivered significant earnings growth with adjusted diluted EPS of $3.68, up 5.1%. Notably, BD raised its full-year adjusted EPS guidance to $14.30-$14.45, reflecting 9.4% growth at the midpoint.Key segment performance included BD Medical growing 14.4%, BD Life Sciences declining 0.5%, and BD Interventional increasing 7.2%. The company announced plans to combine its Biosciences & Diagnostic Solutions business with Waters Corporation and expects to complete the remaining $250 million of its $1 billion share buyback by fiscal year-end.Gross margin improved significantly, with GAAP margin up 160 basis points and adjusted margin up 50 basis points, driven by BD Excellence initiatives. The company maintained its organic revenue growth guidance of 3.0-3.5% for fiscal 2025.

7 months ago

#BDX BD Reports Third Quarter Fiscal 2025 Financial Results

www.stocktitan.net/news/BDX/bd-reports-thir...

0 0 0 0

Medical Giant BD Achieves Unprecedented Supply Chain Excellence with Perfect Score Across All 7 HIRC Categories BD sets new healthcare supply chain benchmark, achieving diamond-level excellence across 7 critical domains. First MedTech company to reach this milestone. Learn more.

7 months ago

#BDX BD Businesses Become First in MedTech to Achieve HIRC's Diamond Badge Across All Supply Chain Resiliency Categories

www.stocktitan.net/news/BDX/bd-businesses-b...

0 0 0 0

BD to Invest $35 Million in Nebraska Facility to Expand Prefilled Flush Syringe Manufacturing to Support U.S. Health Care BD (NYSE: BDX) has announced a $35 million investment to expand its prefilled flush syringe manufacturing capacity at its Columbus, Nebraska facility. The expansion will create approximately 50 new jobs and increase production of BD® PosiFlush™ Prefilled Flush Syringes by hundreds of millions of units annually.The company has already invested over $80 million in the past three years, increasing U.S. production by more than 750 million units, including a 10% increase this year. This investment is part of BD's larger $2.5 billion commitment to enhance U.S. manufacturing capacity over the next five years.The Columbus facility, operating for over 75 years, is the largest manufacturer of prefilled flush devices in the U.S. BD currently operates more than 30 U.S. manufacturing and distribution facilities across 17 states and Puerto Rico, employing over 10,000 people.

7 months ago

#BDX BD to Invest $35 Million in Nebraska Facility to Expand Prefilled Flush Syringe Manufacturing to Support U.S. Health Care

www.stocktitan.net/news/BDX/bd-to-invest-35...

0 0 0 0